Fulcrum Therapeutics, Inc.
FULC
NASDAQ·Healthcare·Biotechnology·Mkt cap $293.7M
$3.84
▼ -0.39%
P/E
-3.17
Mkt Cap
$293.7M
52-Wk Range
$2.83–$15.74
52-Week Range
$2.83 - $15.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 41.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Focused pipeline targeting genetically defined diseases with clear patient populations and reduced development complexity
- Strategic partnerships with Acceleron Pharma and MyoKardia providing access to complementary research, drug targets, and development expertise
- First-in-class potential for losmapimod in FSHD, a rare disease with limited treatment options and strong unmet medical need
Bear Case
1 risk
- High volatility (beta 3.0). Larger-than-normal price swings expected.
Growth
Stable outlook
Emerging player in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+19.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying FULC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of -$0.21 vs -$0.24 consensus (+13.7% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+13.7%
Revenue trend · last 8Q
—
-100%
—
-100%
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
50%
Sell
50%
Median Price Target
—
Latest: Piper Sandler · $3.00 · Jun 2, 2026
vs Industry
How FULC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related